Patents Assigned to INTELLIA THERAPEUTICS, INC.
  • Modified Guide RNAs Comprising an Internal Linker for Gene Editing
    Publication number: 20240150761
    Abstract: This disclosure relates to modified guide RNAs comprising an internal linker for in vitro and in vivo gene editing methods.
    Type: Application
    Filed: December 7, 2023
    Publication date: May 9, 2024
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Sabin Mulepati, Rubina Giare Parmar, Lindsey Jean Stretz, Michelle Young, Jasmine Josephine Bonanno, Seth C. Alexander
  • Compositions and Methods for Genetically Modifying CIITA in a Cell
    Publication number: 20240139323
    Abstract: Compositions and methods for reducing MHC class II protein expression in a cell comprising genetically modifying CIITA for use e.g., in adoptive cell transfer therapies.
    Type: Application
    Filed: June 22, 2023
    Publication date: May 2, 2024
    Applicant: Intellia Therapeutics, Inc.
    Inventors: William Frederick Harrington, Surbhi Goel
  • Compositions and methods for TTR gene editing and treating ATTR amyloidosis
    Patent number: 11965165
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: April 23, 2024
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent
    Publication number: 20240124897
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Application
    Filed: July 31, 2023
    Publication date: April 18, 2024
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Yong Chang, Seth C. Alexander, Kristy M. Wood, Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Polynucleotides, Compositions, and Methods for Genome Editing
    Publication number: 20240076636
    Abstract: Compositions and methods for gene editing. In some embodiments, a polynucleotide encoding Cas9 is provided that can provide one or more of improved editing efficiency, reduced immunogenicity, or other benefits.
    Type: Application
    Filed: April 7, 2023
    Publication date: March 7, 2024
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Christian Dombrowski, Jonathan Douglas Finn, Amy Madison Rhoden Smith, Seth C. Alexander
  • Compositions and Methods for Reducing HLA-A in a Cell
    Publication number: 20240024478
    Abstract: Compositions and methods for reducing HLA-A protein expression in a cell comprising genetically modifying HLA-A for use e.g., in adoptive cell transfer therapies.
    Type: Application
    Filed: June 22, 2023
    Publication date: January 25, 2024
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Surbhi Goel, Yong Zhang, Reynald Michael Lescarbeau, Bradley Andrew Murray, Srijani Sridhar
  • Compositions and Methods for Kallikrein (KLKB1) Gene Editing
    Publication number: 20240018496
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.
    Type: Application
    Filed: July 31, 2023
    Publication date: January 18, 2024
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Shobu Odate, Jessica Lynn Seitzer
  • Compositions and Methods for Reducing MHC Class II in a Cell
    Publication number: 20240016934
    Abstract: Compositions and methods for reducing MHC class II protein expression in a cell comprising genetically modifying CIITA for use e.g., in adoptive cell transfer therapies.
    Type: Application
    Filed: June 9, 2023
    Publication date: January 18, 2024
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Srijani Sridhar, Yong Zhang, William Frederick Harrington, Surbhi Goel
  • Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination
    Publication number: 20240002820
    Abstract: Polynucleotides, polypeptides, compositions, and methods for genome editing using deamination are provided. An mRNA containing an open reading frame (ORF) encoding a polypeptide is provided herein. The polypeptide includes a cytidine deaminase and an RNA-guided nickase, and does not include a uracil glycosylase inhibitor (UGI). A composition provided herein may include two different mRNAs. The first mRNA includes an ORF encoding a cytidine deaminase and an RNA-guided nickase, and the second mRNA includes an ORF encoding uracil glycosylase inhibitor (UGI).
    Type: Application
    Filed: June 9, 2023
    Publication date: January 4, 2024
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Christian Dombrowski, William Frederick Harrington, Ruan Oliveira
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20240002843
    Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
    Type: Application
    Filed: October 13, 2022
    Publication date: January 4, 2024
    Applicants: Novartis AG, Intellia Therapeutics, Inc.
    Inventors: Anthony Edward BOITANO, Michael COOKE, Lloyd B. KLICKSTEIN, Reynald LESCARBEAU, Craig Stephen MICKANIN, Kabungo MULUMBA, Seshidhar Reddy POLICE, Jennifer SNEAD, Susan C. STEVENSON, Morag STEWART, Yi YANG
  • Compositions and methods for immunooncology
    Patent number: 11851659
    Abstract: The present disclosure is directed to genome editing systems, reagents and methods for immunooncology.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: December 26, 2023
    Assignees: Novartis AG, Intellia Therapeutics, Inc.
    Inventors: Jennifer Brogdon, Ming-Wei Chen, Hyungwook Lim, Yi Yang, Morag Stewart, Sarah Hesse
  • Natural Killer Cell Receptor 2B4 Compositions and Methods for Immunotherapy
    Publication number: 20230383252
    Abstract: Compositions and methods for editing, e.g., altering a DNA sequence, within a 2B4 gene are provided. Compositions and methods for immunotherapy are provided.
    Type: Application
    Filed: August 7, 2023
    Publication date: November 30, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventor: Danielle Ryan Cook
  • Lymphocyte Activation Gene 3 (LAG3) Compositions and Methods for Immunotherapy
    Publication number: 20230383253
    Abstract: Compositions and methods for editing, e.g., altering a DNA sequence, within a LAG3 gene are provided. Compositions and methods for immunotherapy are provided.
    Type: Application
    Filed: August 7, 2023
    Publication date: November 30, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventor: Danielle Ryan Cook
  • T-Cell Immunoglobulin and Mucin Domain 3 (TIM3) Compositions and Methods for Immunotherapy
    Publication number: 20230374456
    Abstract: Compositions and methods for editing, e.g., altering a DNA sequence, within a TIM3 gene are provided. Compositions and methods for immunotherapy are provided.
    Type: Application
    Filed: August 7, 2023
    Publication date: November 23, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventor: Danielle Ryan Cook
  • Compositions and methods for TTR gene editing and treating ATTR amyloidosis
    Patent number: 11795460
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: October 24, 2023
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Compositions and Methods for Kallikrein (KLKB1) Gene Editing
    Publication number: 20230295587
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.
    Type: Application
    Filed: August 5, 2022
    Publication date: September 21, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Shobu Odate, Jessica Lynn Seitzer
  • Modified Guide RNAs
    Publication number: 20230287400
    Abstract: This disclosure relates to modified single and dual guide RNAs having improved in vitro and in vivo activity in gene editing methods.
    Type: Application
    Filed: September 1, 2022
    Publication date: September 14, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Amy Madison Rhoden Smith, David V. Morrissey, Walter Strapps
  • Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA)
    Publication number: 20230271997
    Abstract: This disclosure relates to the field of poly-adenylated (poly-A) tails. In some embodiments, a DNA encodes a poly-A tail located 3? to nucleotides encoding a protein of interest, wherein the poly-A tail comprises one or more non-adenine nucleotide.
    Type: Application
    Filed: May 1, 2023
    Publication date: August 31, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventor: Christian Dombrowski
  • Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis
    Publication number: 20230257747
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Application
    Filed: December 9, 2022
    Publication date: August 17, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Polynucleotides, compositions, and methods for genome editing
    Patent number: 11697806
    Abstract: Compositions and methods for gene editing. In some embodiments, a polynucleotide encoding Cas9 is provided that can provide one or more of improved editing efficiency, reduced immunogenicity, or other benefits.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: July 11, 2023
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Christian Dombrowski, Jonathan Douglas Finn, Amy Madison Rhoden Smith, Seth C. Alexander